Company* (Country, symbol)

Company# (Country, symbol)

Type/Product Area

Terms/Details (Month)

Abgenix Inc.

Chiron Corp.

Research license and option agreement under which Chiron will use Abgenix's XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of autoimmune diseases; in a separate agreement, Chiron may use the XenoMouse to generate fully human antibodies to up to 4 cancer targets

Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales (12/99)

CuraGen Corp.

Collaboration to develop and commercialize fully human antibody drugs using Abgenix's XenoMouse technology to generate antibodies for use in treating complex diseases, including cancer and autoimmune disorders; antibodies to cancer antigens in CuraGen's database will be generated exclusively with XenoMouse technology during agreement

Abgenix will purchase $15M of CuraGen stock, and CuraGen will provide research support payments of $1.5M per year; both companies will receive reciprocating milestone and royalty payments for products resulting from the alliance (12/99)

Human Genome Sciences Inc.

Collaboration and technology exchange to identify dozens of human antibody drug candidates for development and commercialization; HGS gains right to use Abgenix's XenoMouse technology to generate fully human monclonal antibody drug candidates to HGS antigens

Under multi-year agreement, HGS will develop and commercialize independently antibody-based drugs arising from the collaboration; Abgenix also has an option in the future to develop and commercialize independently products derived from HGS antigens; companies will pay reciprocal milestones and royalties; in addition, Abgenix and HGS will select up to 2 targets of interest each year for shared development and commercialization (12/99)

Affymetrix Inc.

Qiagen GmbH (subsidiary of Qiagen N.V.; NASDAQ: QGENF)

Development and commercialization agreement for nucleic acid sample preparation solutions optimized for use with Affymetrix GeneChip arrays; agreement expands on general recommendation Affymetrix has been making for use of certain Qiagen products in expression monitoring

Non-exclusive agreement; details ND (11/99)

Alliance Pharmaceutical Corp.

Inhale Therapeutic Systems Inc.

Inhale acquired Alliance's PulmoSpheres particle and particle-processing technology for use in respiratory drug delivery

Alliance will receive $15M in cash and $5M in Inhale stock, plus milestones and royalties; Inhale receives rights to PulmoSpheres technology in the field of respiratory delivery, other related assets and $5M of Alliance stock (10/99)

AVI BioPharma Inc.

SuperGen Inc.

SuperGen acquired equity interest in AVI in conjunction with 11/99 acquisition of negotiating rights in the U.S. to Avicine, AVI's therapeutic cancer vaccine in late-stage development

SuperGen acquired 7.5% of AVI's common stock in exchange for $5M in cash and stock (12/99)

XTL Biopharmaceuticals Ltd.* (Israel)

Collaboration to evaluate and co-develop therapeutics for hepatitis B and hepatitis C; XTL will provide its TrimeraXTL animal models to test AVI's NeuGene antisense compounds against HBV and HCV

XTL will co-develop or receive royalties on compounds identified in the collaboration; further financial details ND (12/99)

Axon Instruments Inc.*

Geron Corp.

Technology collaboration/development of a cellular resolution, high-throughput imaging system for drug discovery

Geron joined Axon's CellPix consortium to develop imaging system for drug discovery; financial terms ND (11/99)

Axys Pharmaceuticals Inc.

Cephalon Inc.

Axys' combinatorial chemistry subsidiary, Axys Advanced Technologies Inc. (AAT), will supply diverse compound screening libraries and chemistry services for use in Cephalon's target-based assays

AAT will receive payment from Cephalon for the delivery compounds, as well as certain future payments if Cephalon uses AAT for chemistry support and services (12/99)

Biohybrid Inc.*

Micromet GmbH* (Germany)

Licensing agreement providing Micromet with exclusive rights to Biohybrid's Activating Hybrid Antibody technology patent, which covers recruitment of cytotoxic T cells from a patient to bind tumor cells using hybrid antibodies

Biohybrid receives up-front milestone and royalty payments in excess of $3M (11/99)

Bioreason Inc.*

Biacore AB(NASDAQ:BCOR; Sweden)

Biacore made an equity investment in Bioreason; companies will share develment costs and will form a joint marketing alliance to promote the software (10/99)

Cellomics Inc.*

ACLARA BioSciences Inc.*

Agreement to develop, manufacture and market the Cell-Chip System for advanced whole-cell analyses in the life science markets; collaboration combines ACLARA's expertise in microfluidics and micro fabrication with Cellomics' skills in cell and molecular biology, fluorescence-based reagents, optical detection, informatics and cell patterning strengths

Companies will seek additional corporate partners to complete the system; additional financial details ND (11/99)

Schenley Park Research Inc.*

Collaboration to develop new analytical software products for data mining of life sciences research; Schenley's data-mining expertise will bolster Cellomics' program to create a systematic knowledge base of the cell

Cellomics has an option to license certain data-mining tools exclusively for cell analysis in life sciences applications;further financial details ND (11/99)

Chiron Corp.

Gilead Sciences Inc.

Settlement of patent suit under which Gilead admits infringement of Chiron's U.S. hepatitis C virus protease patents

Gilead made a lump-sum payment to Chiron, admitted infringement and assigned to Chiron a co-ownership interest to all of Gilead's HCV protease inhibitor research results; as a result of declining a license, Gilead also agreed to cease screening for HCV protease inhibitors and to provide Chiron limited ongoing support in Chiron's similar inhibitor research (12/99)

Connetics Corp.

Soltec Research Pty Ltd. (a subsidiary of F.H. Faulding & Co. Ltd.; Australia)

Connetics licensed certain applications of Soltec's topical delivery technologies, including aerosol foam formulations and Soltec's Liquipatch technology; focus is on dermatological indications

Connetics will pay Soltec $1M in cash and stock, in addition to milestone, development and royalty payments (12/99)

Connetics Corp. and Xoma LLC

The Immune Response Corp.

Connetics and Xoma will assign their T-cell receptor intellectual property to Immune Response, which owns additional TCR technology and will carry forward development of products for chronic connective tissue and autoimmune diseases

Connetics and Xoma will each receive a cash payment, stock in Immune Response and royalties on future sales; Arthur Vandenbark, one of the inventors, will also receive royalties (12/99)

Diversa Corp.*

TerraGen Discovery Inc.*

Cross-licensing agreement for patents covering methods to discover biomolecules of interest

TerraGen obtains a non-exclusive license to Diversa's patents for small-molecule applications; Diversa pays fees to TerraGen for a co-exclusive license to specific TerraGen patents for all fields of use, outside of small-molecule pharmaceutical applications (12/99)

Dynavax Technologies

Stallergénes S.A. (Paris:6567.PA;

Agreement to develop treatments for seasonal allergies in Europe using Dynavax's immunostimulatory oligonucleotide sequences (ISS); initial focus is on clinical development of AIC, a highly purified form of the main ragweed allergen linked to multiple ISS

Stallergénes will have the option to acquire European marketing rights to Dynavax's ISS linked to allergens for treatment of seasonal allergies, in return for equity investments, research and development funding, and milestone and royalty payments; each company will take the lead on development of ISS/allergen conjugates for regionally specific conditions (11/99)

Geneka Biotechnology Inc.* (Canada)

Nova Molecular Inc.* (Canada)

Collaboration agreement for functional gene expression studies into central nervous system diseases; companies will use Geneka's gene expression platform to identify transscriptional factors involved in NMI's lead therapeutic compound and related target pathways

Terms ND (11/9)

GenVec Inc.

Cantab Pharmaceuticals plc

Cantab acquires exclusive option to license GenVec patents related to gene therapy delivery using herpes simplex virus; technology may prove useful to development of gene therapy approaches to neurological disorders

In return for an exclusive multiyear option for commercial licenses to GenVec's HSV patent portfolio, Cantab paid a signing fee and will make additional maintenance payments over the option period; to exercise an option in any disease area, Cantab will pay GenVec a commercial license fee, milestones and royalties on any sales (12/99)

Inspire Pharmaceuticals Inc.*

Genentech Inc.

Collaboration to develop treatments for respiratory disorders including small molecules for cystic fibrosis and chronic bronchitis; research focuses on Inspire's inhaled P2Y2 agonists and expertise in pulmonary hydration and clearance mechanisms

Inspire could receive $78M, including $10M in cash and equity up front, milestones, and potential royalties on net sales; in the U.S., Inspire will lead early development of small molecule for CF and retains co-development and co-promotion rights in exchange for profit-sharing (12/99)

Lexicon Genetics Inc.*

Ligand Pharmaceuticals

Ligand gains non-exclusive sublicense to "positive-negative selection" technology for generating cell lines useful to drug discovery

Ligand gains non-exclusive rights to use the technology under a sublicense; financial details ND

Medarex Inc.

IDM* (France)

Research collaboration using Medarex's HuMAb-Mouse technology for the generation of fully human antibodies to multiple targets; IDM also becomes Medarex's first partner for CTLA-4 Blockade technology to enhance cancer vaccines; IDM will use the technology with its Dendritophages as a cellular vaccine for melanoma and prostate cancer

Medarex could receive research payments, license fees, milestones, and royalties on any sales (12/99)

Molecular Applications Group

Celera Genomics

Celera purchased Panther technology, a functional genomics software tool, from MAG

Purchase; further terms ND (12/99)

MondoGen GmbH (Germany)*

HepaVec AG* (Germany)

HepaVec took a majority stake in MondoGen, thus acquiring access to MondoGen's complementary liver-specific vector technology, based on a modified version of the hepatitis B virus

HepaVec acquired a majority stake in MondoGen; financial details ND (11/99)

MorphoSys AG NeuerMarks:MOR; Germany)

Biosite Diagnostics Inc. (NASDAQ: BSTE)

License agreement under which Biosite's collaborative antibody development program, Biosite Discovery, will provide MorphoSys with a non-exclusive license to use phage display of Fab and/or other multichain antibodies to develop antibodies from MorphoSys' HuCAL antibody libraries; Biosite gains access to certain diagnostic markers MorphoSys has generated under partnerships

Companies will pay each other revenues based on the sale of licensed product (12/99)

Orchid Biocomputer Inc.

Affymetrix Inc.

Development and commercialization agreement for singgle nucleotide polymorphism genotyping assays that combine Orchid's GBA primer extension technology with a new GeneChip array product offering from Affymetrix

Orchid will develop and manufacture GBA primer extension reagent kits that are directed to defined sets of SNPs and that can be customized by the end user; Affymetrix will distribute and manufacture the universal Gene-Chip arrays, and will provide marketing, sales and technical support; Affymetrix invested in Orchid's 1/00 financing as part of the deal (12/99)

OXIS International (France; Nouveau Marche: OXIS)

ND

OXIS assigned rights to its patents related to polyalkalene glycols (PEG) to an undisclosed party; OXIS will retain a non-exclusive perpetual paid-up license to these patents for PEG conjugated superoxide dismutase

OXIS received an up-front cash payment of $0.6M and will receive an additional $0.23M upon FDA approval of the first U.S. product covered by these patents; OXIS also will receive royalties on any products (11/99)

Pangea Systems Inc.*

SUGEN Inc. (wholly owned subsidiary of Pharmacia & Upjohn; NYSE:PNU)

SUGEN licensed Pangea's Clustering and Alignment Tools, which enable companies to cluster and align high volumes of expressed sequence tags and partial gene sequences into full-length gene sequences

Financial terms ND (11/99)

Pharming N.V. (the Netherlands; EASDAQ:PHAR)

Genzyme Transgenics Corp.

Genzyme Transgenics gains non-exclusive license to bovine transgenic technology for use in producing human serum albumin in the milk of cattle

Genzyme Transgenics will pay $0.75M up front, a yearly maintenance fee, milestones and royalties on any products (10/99)

Scios Inc.

Chiron Corp.

Chiron gains a license to Scios' rights to human basic fibroblast growth factor, a stimulator of blood vessel formation and other tissue repair processes

Chiron will pay licensing fees of $12.5M in the form of cash and a forgivable loan; in addition, Scios could receive milestones of $12M, plus royalties on any sales (12/99)

Signal Pharmaceuticals Inc.*

Axys Pharmaceuticals Inc.

Axys gains exclusive, worldwide development and marketing rights to Signal's selective estrogen receptor-beta modulators (SERM-beta) for the treatment of cancer

Signal will receive a license fee, research funding, milestones and royalties; Signal may exercise a profit- and cost-sharing option in the U.S. at a predetermined point in lieu of royalties on product sales (10/99)

Tripos Inc.*

Cyprotex (division of Medeval Ltd.*; UK)

Technology collaboration; enhancement of design of chemical libraries using in vitro pharmacokinetic profiling and the prediction of in vivo drug absorption, distribution, metabolism and excretion

Financial terms ND (11/99)

Notes:

@ This chart covers biotech company deals with other biotech companies, and biotech company deals with device, diagnostics and marketing companies announced between 10/16/99 and 12/31/99. It does not include deals in the area of agricultural biotechnology.

* Private companies are indicated with an asterisk.

# Indicates funding partner, where applicable.

Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 21-22.

OTC BB = Over the Counter Bulletin Board; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed, reported and/or available